GPX4 and obesity due to melanocortin 4 receptor deficiency: GPX4 expression in tumors correlates with lower response to immunotherapy treatments (Supplementary 3 A-B), and GPX4 inhibition synergizes with immune checkpoint inhibitors to reduce tumor burden in models of TNBC [48] without obesity.